Goodwin’s Life Sciences team advised Cullinan Oncology, LLC on its $150 million Series A financing round co-led by the UBS Oncology Impact Fund managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures, an international biotechnology venture capital asset manager investing in breakthrough life science companies. Created by MPM Capital, Cullinan was formed to develop high-value oncology therapeutics with a unique, cost-efficient business model.
Cullinan, led by an accomplished team of oncology researchers, biopharma executives and experienced entrepreneurs, is a company predicated on distributing risk while maximizing optionality through the construction of a diversified portfolio of internally developed as well as externally sourced oncology assets. Cullinan’s scalable model minimizes the fixed costs and inefficiencies of many traditional development approaches through strategic partnerships and a shared services platform.
For additional details on the financing, please read the press release.